Caribou, AvenCell and Amgen Report Preclinical Data in AML; AACR 2023 Analysis 4
Here is a brief preview of this blast: AACR 2023 Analysis 4: Caribou, AvenCell, and Amgen presented preclinical data from their cell therapies in AML. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered: